Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer

References

• Chun SG, Hu C, Choy H. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56–62.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol. 2015;16:187–199.
   PubMed Web of Science ®Google Scholar
• Lee HK, Vaporciyan AA, Cox JD, et al. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003;57(5):1317–1322.
   PubMed Web of Science ®Google Scholar
• Welsh J, Gomez D, Palmer MB, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011;81(5):1336–1342.
   PubMed Web of Science ®Google Scholar
• Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non–small-cell lung cancer. J Clin Oncol. 2018;36(18):1813–1822.
   PubMed Web of Science ®Google Scholar
• Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions. Phys Med Biol. 2008;53(4):1043–1056.
   PubMed Web of Science ®Google Scholar
• Berman A, James S, Rengan R. Proton beam therapy for non-small cell lung cancer: current clinical evidence and future directions. Cancers 2015;7(3):1178–1190.
   PubMed Web of Science ®Google Scholar
• Chang JY, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non–small cell lung cancer: final results of a phase 2 study. JAMA Oncol. 2017;3(8):e172032.
   PubMed Web of Science ®Google Scholar
• Higgins KA, O'Connell K, Liu Y, et al. National Cancer Database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97(1):128–137.
   PubMed Web of Science ®Google Scholar
• Nguyen Q, Ly NB, Komaki R, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115(3):367–372.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010;77(2):357–366.
   PubMed Web of Science ®Google Scholar
• Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1087–1096.
   PubMed Web of Science ®Google Scholar
• Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer). J Thorac Oncol. 2012;7(1):165–176.
   PubMed Web of Science ®Google Scholar
• Inoue T, Widder J, van Dijk LV, et al. Limited impact of setup and range uncertainties, breathing motion, and interplay effects in robustly optimized intensity modulated proton therapy for stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016;96(3):661–669.
   PubMed Web of Science ®Google Scholar
• Liu C, Sio TT, Deng W, et al. Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: a dosimetric comparative study. J Appl Clin Med Phys. 2018;19(6):140–148.
   PubMed Web of Science ®Google Scholar
• Hoffmann L, Alber M, Jensen MF, et al. Adaptation is mandatory for intensity modulated proton therapy of advanced lung cancer to ensure target coverage. Radiother Oncol. 2017;122(3):400–405.
   PubMed Web of Science ®Google Scholar
• Liu W, Schild SE, Chang JY, et al. Exploratory study of 4D versus 3D robust optimization in intensity modulated proton therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):523–533.
   PubMed Web of Science ®Google Scholar
• International Commission on Radiation Units and Measurements (ICRU). Prescribing, recording, and reporting photon beam therapy. ICRU Report 62 (Supplement to ICRU Report 50). Bethesda (MD): ICRU Publications; 1999.
   Google Scholar
• Weistrand O, Svensson S. The ANACONDA algorithm for deformable image registration in radiotherapy. Med Phys. 2015;42(1):40–53.
   PubMed Web of Science ®Google Scholar
• Fredriksson A, Forsgren A, Hårdemark B. Minimax optimization for handling range and setup uncertainties in proton therapy. Med Phys. 2011;38(3):1672.
   PubMed Web of Science ®Google Scholar
• Albertini F, Hug EB, Lomax AJ. Is it necessary to plan with safety margins for actively scanned proton therapy? Phys Med Biol. 2011;56(14):4399–4413.
   PubMed Web of Science ®Google Scholar
• Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol. 2008;53(4):1027–1042.
   PubMed Web of Science ®Google Scholar
• Korevaar EW, Habraken SJM, Scandurra D. Practical robustness evaluation in radiotherapy – a photon and proton-proof alternative to PTV-based plan evaluation. Radiother Oncol. [cited 2019 Sep 3]. DOI:10.1016/j.radonc.2019.08.005.
   Web of Science ®Google Scholar
• Meijers A, Jakobi A, Stützer K, et al. Log file-based dose reconstruction and accumulation for 4D adaptive pencil beam scanned proton therapy in a clinical treatment planning system: implementation and proof-of-concept. Med Phys. 2019;46(3):1140–1149.
   PubMed Web of Science ®Google Scholar
• Unkelbach J, Bortfeld T, Martin BC, et al. Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning. Med Phys. 2009;36(1):149.
   PubMed Web of Science ®Google Scholar
• Li Y, Kardar L, Li X, et al. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014;41:1–7.
   PubMed Web of Science ®Google Scholar
• Ribeiro CO, Meijers A, Korevaar EW, et al. Comprehensive 4D robustness evaluation for pencil beam scanned proton plans. Radiother Oncol. 2019;136:185–189.
   PubMed Web of Science ®Google Scholar
• Kadoya N, Nakajima Y, Saito M, et al. Multi-institutional validation study of commercially available deformable image registration software for thoracic images. Int J Radiat Oncol Biol Phys. 2016;96(2):422–431.
   PubMed Web of Science ®Google Scholar
• Kierkels RGJ, den Otter LA, Korevaar EW, et al. An automated, quantitative, and case-specific evaluation of deformable image registration in computed tomography images. Phys Med Biol. 2018;63(4):045026.
   PubMed Web of Science ®Google Scholar
• Ribeiro CO, Knopf A, Langendijk JA, et al. Assessment of dosimetric errors induced by deformable image registration methods in 4D pencil beam scanned proton treatment planning for liver tumours. Radiother Oncol. 2018;128(1):174–181.
   PubMed Web of Science ®Google Scholar
• Salama JK, Pang H, Bogart JA, et al. Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904. Lung Cancer 2013;82(3):436–440.
   PubMed Web of Science ®Google Scholar
• PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257–263.
   PubMed Web of Science ®Google Scholar
• Speirs CK, DeWees TA, Rehman S, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol. 2017;12(2):293–301.
   PubMed Web of Science ®Google Scholar